HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Herceptin (trastuzumab) is used in patients with breast cancer who have HER2 (ErbB2)-positive tumours. However, its mechanisms of action and how acquired resistance to Herceptin occurs are still poorly understood. It was previously thought that the anti-HER2 monoclonal antibody Herceptin inhibits HE...
Guardado en:
Autores principales: | Merel Gijsen, Peter King, Tim Perera, Peter J Parker, Adrian L Harris, Banafshé Larijani, Anthony Kong |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c5080a2bcf7e4d1e999a564bea1a2958 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition.
por: Véronique Calleja, et al.
Publicado: (2009) -
3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.
por: Aamir Ahmad, et al.
Publicado: (2013) -
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
por: Liyun Luo, et al.
Publicado: (2021) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Avisek Majumder, et al.
Publicado: (2021) -
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem DD, et al.
Publicado: (2014)